Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center

Annals of Surgical Oncology

Volumn 16, Issue 7, 2009, Pages 1852-1859

  Alexander Jr , H Richard ^a,b   Bartlett, David L ^b   Libutti, Steven K ^b   Pingpank, James F ^b   Fraker, Douglas L ^b   Royal, Richard ^b   Steinberg, Seth M ^b   Helsabeck, Cynthia B ^b   Beresneva, Tatiana H ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; CARCINOEMBRYONIC ANTIGEN; CREATININE; DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR;

ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FEVER; DRUG INTERMITTENT THERAPY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; HYPOTENSION; INOPERABLE CANCER; LIVER FAILURE; LIVER METASTASIS; LIVER PERFUSION; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PARTIAL THROMBOPLASTIN TIME; PLEURA EFFUSION; PROSPECTIVE STUDY; PROTHROMBIN TIME; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; WOUND INFECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649158711     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0482-9     Document Type: Article

References (27)

1. Stangl R, tendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405-10.
2. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol. 2006;24:3347-53.
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45.
4. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluourouracil- leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil- leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059-69.
5. Rothenberg ML. Current status of second-line therapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2004;4(1):S16- 21.
6. Grover A, Alexander HR, Jr. The past decade of experience with isolated hepatic perfusion. Oncologist. 2004;9:653-64.
7. Alexander HR, Jr., Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol. 2005;12:138-44.
8. Libutti SK, Bartlett DL, Fraker DL, Alexander HR. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg. 2000;191:519-30.
9. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;129:176-87.
10. Barker WC, Andrich MP, Alexander HR, Fraker DL. Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med. 1995;22:1242-8.
11. Lans TE, Bartlett DL, Libutti SK, Gnant MFX, Liewehr DJ, Venzon DJ, et al. Role of tumor necrosis factor (TNF) on toxicity and cytokine production following isolated hepatic perfusion (IHP). Clin Cancer Res. 2001;7:784-90.
12. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;129:176-87.
13. Goldberg RM, Rothenberg ML, van CE, Benson AB, Ill, Blanke CD, Diasio RB, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12:38-50.
14. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
15. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-14.
16. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhii SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23:9243-9.
17. Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006;13:58-65.
18. Benoist S, Brouquet A, Penna C, Julie C, El HM, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939- 45.
19. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-8.
20. Breedis C, Young G. Blood supply of neoplasms of the liver. Am J Pathol. 1954;30:969-85.
21. Ridge JA, Bading JR, Gelbard AS, Benua RS, Daly M. Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein. Cancer. 1987;59:1547- 53.
22. Alexander HR, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist. 2000;5:416-24.
23. Posner MC, Lienard D, Lejeune FJ, Rosenfelder D, Kirkwood J. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am. 1995;1:274-80.
24. Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MF, et al. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood. 2002;100:1334-9.
25. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986;163:740-5.
26. Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH, Jr., Bodoky G, et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol. 2008;26:4544-50.
27. Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/ leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol. 2004;22:4701-9.